BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Date iCal//NONSGML kigkonsult.se iCalcreator 2.20.4//
METHOD:PUBLISH
X-WR-CALNAME;VALUE=TEXT:ÌÇÐÄÔ­´´
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:STANDARD
DTSTART:20201101T020000
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20210314T020000
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
UID:calendar.403721.field_event_date.0@www.wright.edu
DTSTAMP:20260220T002846Z
CREATED:20201013T181307Z
DESCRIPTION:Unconventional Metal-Based Drugs as Potential Therapeutic Treat
 ments for Breast Cancer.Marie Contell\, The City University of New York. A
 bstract: Metal-based chemotherapeutics such as platinum-based drugs in com
 bination or monotherapy regimes are used to treat a large number of cancer
 s. However\, their efficacy is still hindered by clinical problems\, inclu
 ding acquired or intrinsic resistance\, a limited spectrum of activity\, a
 nd high toxicity leading to significant side effects. A number of unconven
 tional metal-based compounds highly effective in cancers resistant to cisp
 latin and other chemotherapeutics\, have been described over the past deca
 de (including recent successful clinical trials). In this context\, our la
 boratory is exploring some of these metallodrugs as potential treatments f
 or different types of breast cancer (still the deadliest type of cancer fo
 r women). Two types of breast cancers have a direr prognosis and are espec
 ially difficult to treat: triple negative and HER-2 positive breast cancer
 s. We will present our latest work on Ruthenium(II) compounds containing p
 -cymene and iminophosphorane ligands which have been extremely efficacious
  in triple negative breast cancer (both in vitro and in vivo).1\,2 New der
 ivatives include florescent analogues. We are also working on strategies f
 or the delivery of metal-based drugs so that they can be efficiently relea
 sed at the specific tumor site to improve selectivity\, bioavailability an
 d blood circulation times.3\,4 We will report on strategies to target HER-
 2 breast cancers by using antibody drug conjugates containing Trastuzumab 
 and gold(I) cytotoxic species.Meeting InformationMeeting link: https://wri
 ght.webex.com/wright/j.php?MTID=m12ded79e71d125543af41140754333b7Meeting n
 umber:  172 925 4036Password: wsuchemistry987 Event Webpage: https://wrigh
 t.webex.com/wright/j.php?MTID=m12ded79e71d125543af41140754333b7
DTSTART;TZID=America/New_York:20201016T153000
DTEND;TZID=America/New_York:20201016T170000
LAST-MODIFIED:20201013T201602Z
SUMMARY:Chemistry Seminar
URL;TYPE=URI:/events/chemistry-seminar-0
END:VEVENT
END:VCALENDAR